Table 1.
Short-term studies.
| Authors | Type of Study | Population | Design | Baseline Vitamin D ng/L/nmol/L |
Methods Vitamin D |
Superiority of Calcifediol | Other Data |
|---|---|---|---|---|---|---|---|
| Russo et al. [12] | Open | 18 pre- and postmenopausal females |
One arm with 500 μg of 25D3. 16 weeks |
18.1 ± 12.5 ng/mL 45.1 ± 31.1 nmol/L |
RIA | NA | 88% > 30 ng/mL (74.8 nmol/L) |
| Minisola et al. [8] | RCT | 87 postmenopausal females | Three arms of 25D3 20μg/day,40μg/day,125μg/week. 16 weeks | 16.5 ± 7.5 ng/mL 41.1 ± 18.7 nmol/L |
Chemiluminiscence | NA | 100% > 30 ng/mL (74.8 nmol/L) |
| Cashman et al. [13] | RCT | 56 adults (25m, 31f) > 50 years | Three arms of 20μg/day D3, 7μg/day and 20μg/day 25D3. 10 weeks | 17.4 ± 4.9 ng/mL 43.6 ± 122.3 nmol/L |
ELISA | YES | >Dose 20μg/day 25D3 |
| Bischoff-Ferrari et al. [14] | RCT | 20 postmenopausal females | Two arms, 20μg/day D3 vs20μg/day 25D3. 16 weeks | 13 ± 3.8 ng/mL 32.4 ± 9.4 nmol/L |
HPLC-MS/MS | YES | - |
| Jetter et al. [11] | RCT | 35 females aged 50–70 years | 7 arms:20μg/day and 140μg/week of D3 vs 20μg/day and 140 μg/week of 25D3 and combination of both arms. 15 weeks |
13 ± 5 ng/mL 32.4 ± 12.4 nmol/L |
HPLC-MS/MS | YES | Long-term kinetics similar between the two supplements |
| Shieh et al. [15] | RCT | 35 subjects aged >18 years | Two arms 60μg/day of D3 vs 20μg/day of 25D3. 16 weeks | <20ng/ml | HPLC-MS/MS | YES | Determination of free vitamin D with superiority of calcifediol |
| Perez-Castrillón et al. [16] | RCT | 303 postmenopausal females | Two arms 625μg/month D3 vs 266μg/month 25D3. 16 weeks | 13 ± 3.9 ng/mL 32.4 ± 9.7 nmol/L |
Chemiluminiscence | YES | Greater efficacy at one month and four months for both total vitamin D and free vitamin D |
RIA: Radioimmunoassay; HPLC: Liquid chromatography; HPLC-MS/MS: Liquid chromatography coupled to tandem mass spectrometry detection.